Acute Ocular Pain Market Research Report 2024-2030: Infections, Glaucoma, and Inflammation Fuel Market Growth as New Pharmaceutical Advancements Boost Treatment Options Dublin, Oct. 23, 2024 (GLOBE NEWSWIRE) -- The "Global Acute Ocular Pain Market (2024 Edition): Market Size, Trends, Opportunities and Forecast by Source of Pain, Treatment Type, Sales Channel,...

OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain Neuropathic corneal pain (NCP) is listed in the National Organization for Rare Disorders (NORD) as an orphan diseaseOKYO is the first company to have an IND application granted by the FDA for NCP The...

OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye Disease...

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101 OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief

OTC Artificial Tears Markets, Size, Global Forecast 2024-2030: Industry Trends, Share, Growth, Insight, Top Companies Analysis Dublin, March 20, 2024 (GLOBE NEWSWIRE) -- The "OTC Artificial Tears Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Top Companies Analysis"...